Clinical trial
Gemcitabine in Treating Children With Relapsed or Refractory Acute Lymphoblastic…
NCT00006462 · Children's Oncology Group, Other · Completed
Key facts
| NCT number | NCT00006462 |
|---|---|
| Title | Gemcitabine in Treating Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia |
| Official title | A Phase II Study of Gemcitabine (NSC #613327) in Children With Relapsed Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia |
| Lead sponsor | Children's Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | gemcitabine hydrochloride |
| Enrollment | 32 |
| Start date | Apr 1, 2001 |
| Primary completion | Aug 1, 2003 |
| Completion | Sep 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 20, 2014 |
| Countries | Australia, Canada, Netherlands, New Zealand, Puerto Rico, Switzerland, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: